MARTINSRIED/MUNICH, GERMANY and PRINCETON, NJ--(Marketwire - May 15, 2009) - GPC Biotech
AG (FRANKFURT: GPC) today announced two corporate events as follows:
- The Company will hold a call to discuss first quarter financial results
and provide a business update on May 28th. This call was previously
planned for May 19th. The call will be held on May 28 at 15:00 CET/9:00 AM
ET. The results will be published on May 28 in advance of the conference
call.
Participants may listen via live webcast, accessible through the GPC
Biotech Web site at www.gpc-biotech.com, or via telephone. A replay will be
available on the Web site following the live event. The call will be
conducted in English. The dial-in numbers for the call are as follows:
Participants from Europe: +49 (0)69 667775756 or +44 (0)20 3003 2666
Participants from the U.S.: 1 646 843 4608
- The Company also announced that the Annual Shareholders' Meeting has been
scheduled for June 23, 2009. At this meeting, shareholders will be asked
to approve the merger agreement for the planned combination with Agennix,
Incorporated in a new German company. The meeting will be held at 10:00
CET at the Alte Kongresshalle, Theresienhöhe 15 (Schwanthalerhöhe) in
Munich. The agenda for the meeting and related documents are posted on the
Company's website at www.gpc-biotech.com in the Investor Relations section.
About GPC Biotech
GPC Biotech AG is a publicly traded biopharmaceutical company focused on
developing anti-cancer drugs. The Company currently has two programs in
clinical development: satraplatin, an oral platinum compound and
RGB-286638, a multi-targeted protein kinase inhibitor. On February 18, 2009
the Company announced plans to combine its business with U.S.-based
Agennix, Incorporated in a new German company. Agennix, a privately held
biotechnology company, is developing oral talactoferrin, a product
candidate that is currently in Phase 3 trials for non-small cell lung
cancer. GPC Biotech AG is headquartered in Martinsried/Munich (Germany) and
has a wholly owned U.S. subsidiary in Princeton, New Jersey. For additional
information, please visit GPC Biotech's Web site at www.gpc-biotech.com.
This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of GPC Biotech. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause
future results, performance or achievements to differ significantly from
the results, performance or achievements expressed or implied by such
forward-looking statements. Actual results could differ materially
depending on a number of factors, and we caution investors not to place
undue reliance on the forward-looking statements contained in this press
release. Forward-looking statements speak only as of the date on which they
are made and GPC Biotech undertakes no obligation to update these
forward-looking statements, even if new information becomes available in
the future.
